The Vitalize Clinical Study is evaluating an investigational once-weekly oral medication for adults aged 18–64 who have been diagnosed with depression. The study will compare the investigational medication to a placebo to better understand its safety and potential effect on depressive symptoms.
Participation lasts about 3 months and includes a screening period, weekly clinic visits for 6 weeks, and a follow-up phone call. Screening may involve health assessments such as blood tests, questionnaires, ECG and EEG measurements, and other evaluations to confirm eligibility. During the study, participants come to the clinic once each week to receive either the study medication or placebo and complete health and symptom assessments.
All study-required tests, procedures, and visits are provided at no cost. Participants will also be closely monitored by the clinical study team throughout their involvement.
.png){kind=icon}
All study visits occur at UAB Huntsville Regional Medical Campus
You may qualify if you have been diagnosed with depression.
Participants attend weekly visits for 6 weeks.
.png){kind=icon}
You may receive the investigational drug or placebo.
There is no cost to participate. If you qualify, you will receive study-required visits, assessments, and study medication at no cost.
Participants will be paid $200 per completed in-clinic visit, may be reimbursed up to $23 per clinic visit for meal expenses, up to $51 per clinic visit for travel expenses, and will be paid $25 per night (up to 6 nights total) for using the home sleep headband device. Compensation is provided only for completed visits.
.png)
This study is testing an investigational once-weekly medication to better understand its safety and potential to help reduce symptoms of depression.
No. All study-required visits, assessments, and procedures are provided at no cost to you.
All visits occur at UAB Huntsville Regional Medical Campus, including screening, weekly treatment visits, and follow-up.
Yes. Your information will be handled confidentially, and only authorized study personnel and regulatory representatives may access it.
